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tumor response. However, assessment of tumor response 
following CRT and prior to radical surgery may identify 
patients with complete clinical response that could be 
managed by organ preserving strategies. These strategies 
may include transanal local excision (by endoscopic 
microsurgery platforms – TEMs) or even no immediate 
surgery (known as the Watch & Wait strategy). Local 
excision in this setting (in a complete clinical response) 
has the advantages of providing histological confirmation 
of complete primary tumor regression and still provide an 
organ-preservation alternative. However, the morbidity 
of local excision may be quite significant due to the risk 
of wound dehiscences and subsequent functional 
detrimental consequences. Even in patients with 
(unexpected) residual cancer, the need for completion 
TME may result in worse outcomes when compared to 
TME alone. On the other hand non-operative management 
requires a very strict follow-up (Watch & Wait Strategy). 
It avoids unnecessary postoperative morbidity, including 
long-term urinary, sexual, and fecal continence 
dysfunctions and the frequent need for temporary or 
definitive stomas associated with TME and TEMs. Critical 
aspects in this treatment strategy include timing and 
studies (clinical, endosopic and radiological) for the 
assessment of tumor response. Many studies have 
suggested that longer intervals between RT completion 
and assessment of tumor response were associated with 
increased rates of complete response even though one 
recent randomized study has challenged this assumption. 
Clinical and endoscopic assessment using strict criteria 
have been used for the selection of patients based on the 
presence of whitening of the mucosa, teleangiectasia and 
minimal loss of pliability of the rectal wall in the absence 
of any ulceration, stenosis or mass. Radiological studies 
with high-resolution magnetic resonance (MR) with or 
without diffusion-weighted series has been the preferred 
method of assessment of response and the presence of 
low-signal intensity areas are usually consistent with a 
complete response. With the use of these studies, 
selection of patients for a non-immediate surgical 
approach (without TME or TEMs) may provide good 
oncological outcomes and excellent functional results. 
Local recurrences may develop in nearly 25-30% after 3 
years from initial tumor response assessment. Most local 
recurrences have an endoluminal component (90%) and 
are amenable to simple clinical and endoscopic 
detection. Even patients that do develop local 
recurrences may undergo salvage surgery with apparent 
no oncological compromise. In this setting, after a 
complete clinical response in selected patients and 
expert centers, the preferred initial approach should be 
non-immediate surgical resection and strict follow-up. 
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Abstract text  
Tumor-targeted fluorescence imaging has the potential to 
revolutionize current practice of oncologic surgery by 
selectively highlighting malignant tissue during surgery 
and other minimal invasive procedures. Various targets 
were explored for real-time tumor visualization by 
different research groups. Carcinoembryonic antigen 
(CEA) is overexpressed in the majority of colorectal 
cancers (CRC) and is a promising target for CRC imaging. 
Therefore, a dose-escalating study was performed by our 
group to determine pharmacokinetics (PK) and 
tolerability of SGM-101, a novel fluorescent anti-CEA 
monoclonal antibody, and to investigate the feasibility to 
detect rectal cancer with fluorescence imaging in real-
time. Nine patients with primary and 17 (expansion 
cohort) with recurrent or with peritoneal metastases 
(scheduled for HIPEC) were included in this study. SGM-
101 did not cause any treatment-related adverse events 
and a dose of 10 mg, administered four days before the 
surgical procedure, showed the highest tumor-to-
background ratio. In the expansion cohort, 19 (43% of all 
lesions) additional malignant lesions were detected using 
fluorescent imaging, which changed the treatment 
strategy in 6/17 patients (32%). This study presents the 
first clinical experience of CEA-targeted detection of CRC 
and demonstrates that SGM-101 can influence per-
operative clinical decision-making in a substantial 
number of patients. In our opinion, CEA-targeted 
fluorescence imaging might also be very useful for locally 
advanced rectal cancers where fibrosis and tumor tissue 
are difficult to differentiate intraoperatively after neo-
adjuvant chemo-radiotherapy and pre-operative MRI 
imaging is neither sufficiently sensitive, this newly 
developed modality can hopefully be of added value. In 
addition, following the absence of fluorescence in two 
resected specimens of primary rectal cancer patients 
with a pCR, a promising future application of SGM-101 
could be screening for tumor (re)growth during Watch 
and Wait treatment strategies. Latter organ sparring 
strategies will be addressed during the lecture as well as 
the application of other tumor targeting agents (e.g. 
Avastin-800CW, Cetuximab-800CW) for this application.  
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Abstract text  
The watch-and-wait strategy (w&w) for patients with 
rectal cancer achieving clinical complete response (cCR) 
after preoperative radiotherapy is gaining momentum, 
even though it is still considered as experimental 
treatment. Such a strategy may use an “accidental” or 
“intentional” approach. The former confers routine 
indications and schedules of radio(chemo)therapy; the 
latter consists of extended indications and/or higher 
doses of radio(chemo)therapy. The first approach seems 
to be currently more accepted  by the medical 
community. After routine preoperative chemoradiation of 
an average patient population, about 10% cCRs can be 
expected. This rate increases to about 30% for tumours 
up to 5 cm and involving less than 50% of the bowel 
circumference. Thus far, w&w has been possible only 
after chemoradiation. For short-course radiotherapy (5 x 
5 Gy) and immediate surgery, the interval between 
radiation and operation is too short for tumours to 
disappear. The Stockholm III randomised trial comparing 
short with long interval after 5 x 5 Gy has shown 
oncological safety for the long interval. Additionally, this 
trial has demonstrated 12% of pathological complete 
responses after the long interval; another study has also 
shown a clinically relevant rate of cCR. Thus, short-
course radiation with a long interval can be used for the 
“accidental” approach of w&w. 
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Abstract text  
Recent years have seen increased focus on organ 
preservation and non-surgical management strategies for 
rectal cancer, and this has resulted in considerable 
interest in radiotherapy dose-escalation approaches. 
There are reasonably good data to suggest that there may 
exist a dose response relationship for pathological tumour 
regression after preoperative (chemo-)radiotherapy (see 
e.g. Appelt et al, IJROBP 2013). A number of patient and 
	  
S122	   	   ESTRO	  37	  
tumour specific factors may influence this relationship; 
such as tumour volume, lymph node involvement, and 
distance from anal verge. However, it is still unclear 
whether such a dose-response relationship also exists for 
clinical complete response (cCR) to treatment – and 
importantly, whether increase in cCR rates by dose-
escalation will translate into improved long term local 
control without surgery. Existing studies using dose 
escalation for non-surgical management will be briefly 
reviewed, and an analysis of the relationship between 
tumour dose and 2-year local control in published studies 
will be presented. If dose escalation is to be attempted, 
several potential radiotherapy modalities exist. They 
include external beam boost, endorectal brachytherapy 
and contact X-ray therapy (Papillon technique). The 
technical challenges of treatment optimization and 
delivery will be summarised for each technique, including 
(lack of) organ at risk definitions and dose constraints. 
Tumour doses achievable with the three techniques will 
also be mentioned. An additional issue concerns patient 
selection: patients most benefitting from dose escalation 
may be those with small, early cancers who we would not 
usually be irradiated at all; and there may be a subset of 
patients with high risk of surgical morbidity and mortality 
who will have a better risk/benefit ratio with dose 
escalation. These challenges will be discussed. Finally, 
ongoing and planned trials of dose escalation in this 
setting will be covered. They include the OPERA trial 
(NCT02505750), the Canadian MORPHEUS study 
(NCT03051464), the Danish Watchful Waiting II study 
(NCT02438839), and the Dutch RECTAL-BOOST 
(NCT01951521) and HERBERT II studies. 
 
 
Symposium: Cosmetic appearance after brachytherapy  
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Abstract text  
The long-term success of Interventional Radiotherapy 
(brachytherapy) can be evaluated in terms of disease free 
survival and rate of toxicities. In the past, local control 
was in focus of the analyses and reporting adverse effects 
was usually reduced to functional disorders. With the 
introduction of new technologies in this field such as 
image guided and intensity modulated interventional 
radiotherapy (I-RT), more attention is dedicated for 
preventing toxicity also in terms to achieve not only 
functional but also cosmetic well being of the patients. 
Nowadays, I-RT represent the highest level of technology 
and interdisciplinarity. In some anatomic sites, such as 
breast, H&N and skin, the measurement of the treatment 
realted cosmetic changes is usually one of the main study 
end points. Furthermore, published experiences showed 
that the cosmetic outcome has a significant influence on 
quality of life (QoL). Nevertheless, the cosmetic 
assessment in I-RT remains a complex issue since non-
standardized evaluation systems usually work with very 
different methods. Moreover, especially in the past, 
cosmesis was not accurately measured and often 
underestimated with a confusion/overlap with late 
toxicity. There are many ways to evaluate this topic. 
Some systems use qualitative, others quantitative 
methods. Additionally, a cosmetic evaluation system 
could be subjective or objective. Some groups published 
their experiences using specific scoring systems (SS) for 
radiotherapy, others, considering the nature of this 
procedure, preferred a system used in the post-surgery 
assessment. The most frequently applied systems are: 
EORTC-RTOG, LENT-SOMA, CTCAE, Harvard NSABP, Breast 
Retraction Assessment (BRA), Facelift Outcomes 
Evaluation, the Rhinoplasty Outcomes Evaluation (ROE), 
the Blepharoplasty Outcomes Evaluation (BOE), and the 
Skin Rejuvenation Outcomes Evaluation (SROE). Recently, 
new technologies are involved for evaluation of cosmetic 
results, which can provide an objective estimation of the 
treatment effects through the use of high definition 
images, 3D scanners or photogrammetric methods. All of 
these are very useful tools for absolute but also for 
relative evaluation, especially for the comparison with a 
benchmark or other treatment. Moreover, methods using 
dedicated software solutions are spreading in the clinical 
practice. In conclusion, the attention to psychological 
and social aspects in modern oncology is an important 
factor to be considered in the choice of an optimal 
treatment. The standardized objective cosmetic 
assessment could play a central role for analyzing the 
results of interventional radiation therapy, especially for 
the comparison with those of other treatments such as 
external beam radiotherapy or surgery. 
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Abstract text  
Multiple phase 2 and two phase 3 randomized trials 
proved the non-inferiority of APBI with interstitial 
HDR/PDR brachytherapy (BT) in terms of local control 
and overall survival compared with whole-breast 
irradiation (WBI). Cosmetic outcome was reported good 
to excellent in the majority multicatheter BT-based APBI 
trials. However cosmetic results based on direct 
comparison between APBI and WBI were only reported 
from the Hungarian and GEC-ESTRO phase 3 trials.  In the 
Hungarian APBI trial (n=258), 10-year cosmetic results 
were significantly better after HDR BT alone compared to 
WBI: the rate of excellent-good cosmetic result was 81% 
in the APBI arm and 63% in the WBI arm (p<0.01). The 
rate of excellent-good cosmesis in the APBI group was 
85% after HDR BT and 72.5% after external beam 
electrons (p=0.97), whereas in the WBI group it was 67% 
using 6-9 MV photons and only 48% using telecobalt 
(p=0.08). In the GEC-ESTRO APBI trial (n=1184), 5-year 
cosmetic results were similar in patients treated with 
HDR/PDR BT or WBI: according to patients’ view, 92% in 
the APBI group versus 91% in the WBI group had excellent 
to good cosmetic results (p=0.62); when judged by the 
physicians, 93% and 90%, respectively, had excellent to 
good cosmetic results (p=0.12).  Furthermore, neither 
APBI nor WBI deteriorated the cosmesis during the years 
of follow-up, as represented by the stability of cosmetic 
outcomes over time.       Findings from prospective 
randomized trials confirm that multicatheter BT-based 
APBI is not only as effective as WBI but also provides at 
least equivalent cosmetic outcome compared with 
conventional WBI.  
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Abstract text  
Survival in head and neck rhabdomyosarcoma (HNRMS) 
patients is improving, with current overall survival rates 
around 66–97%. However, the majority of patients needs 
radiotherapy potentially combined with surgery to 
achieve and maintain local control. HNRMS patients are 
